{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Adaptive Biotechnologies Corporation"},"Symbol":{"label":"Symbol","value":"ADPT"},"Address":{"label":"Address","value":"1165 EASTLAKE AVENUE EAST SUITE 200, SEATTLE, Washington, 98102, United States"},"Phone":{"label":"Phone","value":"+1 206 659-0067"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.adaptivebiotech.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Chad Robins","title":"Chairman &amp; Chief Executive Officer"},{"name":"Harlan Robins","title":"Chief Scientific Officer"},{"name":"R. Mark Adams","title":"Chief Operating &amp; Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}